Trial site
NeuroProtect Sp. z o.o.
Warsaw, 01-684, PolandEU-13 widening countryNot linked to an institution yet
- 13running trials
- 3closed trials
The trials here
What the 16 trials at this site are about, from their registry records.
- Phase
- Phase 29 trials
- Phase 36 trials
- Phase 1/21 trial
- Status
- Recruiting8 trials
- Active, not recruiting4 trials
- Completed3 trials
- Not yet recruiting1 trial
- Lead sponsor
- UCB Biopharma SRL3 trials
- Hoffmann-La Roche2 trials
- Immunic AG2 trials
- Aurinia Pharmaceuticals Inc.1 trial
- Celgene Corp.1 trial
- and 7 more
Running trials
Recruiting
Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease
NCT07781644· Phase 2· Hoffmann-La Roche· Source
Recruiting
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
NCT07465289· Phase 3· UCB Biopharma SRL· Source
Recruiting
SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures
2025-520587-18-00· Phase 2· Supernus Pharmaceuticals Inc.· Source
Recruiting
A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients with Generalized Myasthenia Gravis
2025-525127-27-00· Phase 1/2· Aurinia Pharmaceuticals Inc.· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
NCT07463521· Phase 3· UCB Biopharma SRL· Source
Recruiting
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
2025-521546-23-00· Phase 3· Novartis Pharma AG· Source
Recruiting
Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants with Multiple Sclerosis Spasticity
2024-517745-14-00· Phase 2· Celgene Corp.· Source
Active, not recruiting
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
NCT06643481· Phase 2· Novartis Pharmaceuticals· Source
Recruiting
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients with Myasthenia Gravis
2023-507539-40-00· Phase 2· NMD Pharma A/S· Source
Active, not recruiting
A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis.
2022-501622-37-00· Phase 3· Celltrion Inc.· Source
Active, not recruiting
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
NCT05269004· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
NCT05201638· Phase 3· Immunic AG· Source
Active, not recruiting
MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)
NCT03846219· Phase 2· Immunic AG· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error